ABSTRACT BACKGROUND Complete revascularization may improve outcomes compared with an infarct-related artery (IRA)-only
The mechanisms leading to improved clinical outcomes are currently unclear. However, there is concern that PCI to non-IRAs may be associated with additional procedural-related infarction (5). These well-described type 4a myocardial infarctions (MIs) (6) cannot be detected by conventional enzymatic markers at the time of PPCI because the associated increases are relatively small compared with the large rise in enzymes caused by the STEMI itself. Cardiovascular magnetic resonance (CMR) is able to precisely characterize areas of myocardial injury following myocardial ischemia. The myocardium at risk becomes edematous (7) , and late gadolinium-enhanced (LGE) imaging allows the accurate detection and quantification of infarct size and microvascular obstruction (MVO) (8) .
Infarct size (9) and MVO (10) measured on CMR are both strong medium-term prognostic markers following PPCI. There are no CMR data as yet in the literature on patients undergoing complete revascularization for multivessel disease at the time of PPCI.
The primary aim of the current pre-specified substudy was to assess whether a complete revascularization strategy, due to causing additional infarcts in the non-IRA territories, was associated with greater infarct size than an IRA-only strategy in patients randomized in CvLPRIT. Additionally, we aimed to assess whether myocardial salvage and myocardial ischemia at follow-up CMR were different in the 2 groups.
METHODS
STUDY DESIGN. The design and rationale of the study have been published previously (11) . Briefly, CvLPRIT CMR was a pre-specified substudy of a multicenter, McCann et al.
RANDOMIZATION AND TREATMENT. Eligible patients presenting with STEMI within 12 h were randomized, after verbal assent and coronary angiography, but before PCI to the culprit lesion, to either IRA-only or in-hospital complete revascularization.
Randomization was stratified by infarct location (anterior/non-anterior MI) and time to presentation (>3 or #3 h). PCI was performed according to current guidelines. Written informed consent for continued participation in the study was obtained on the day(s) following the PPCI, once the patient was able to understand and retain the information.
ANGIOGRAPHIC ANALYSIS. Pre-and post-PPCI epicardial coronary flow was assessed using Thrombolysis
In Myocardial Infarction (TIMI) scoring (12). Collateral flow to the IRA pre-PPCI was graded using the Rentrop system (13). Quantitative coronary angiography was undertaken using QAngioXA v1.0 software (Medis, Leiden, the Netherlands). PRE-DISCHARGE CMR. CMR was performed during the index admission and after non-IRA PCI in those patients in the complete revascularization group in whom the procedure was staged. The protocol was similar to that previously described (14) with the addition of T2-weighted short tau inversion recovery (T2w-STIR) imaging for the detection of edema and is shown in Figure 2 within the myocardium was seen, these patients were excluded from analysis of the area at risk (AAR).
LV volumes and mass were calculated from cine images as previously described using QMass v7.1 heart failure, and ischemia-driven revascularization.
Additional secondary endpoints included cardiovascular death, individual components of the primary endpoint, and the safety endpoints stroke, major bleeding, and contrast-induced nephropathy. Data were collected by an independent clinical trials unit (Royal Brompton Hospital, London, England) and events adjudicated by blinded clinicians.
STATISTICAL ANALYSIS. The primary outcome was infarct size (expressed as a % of LV mass) on pre-discharge CMR, which was analyzed on a log-transformed scale, as it is generally right-skewed.
Primary analysis was on an intention-to-treat basis of all randomized patients according to treatment group who completed the pre-discharge CMR. The result was adjusted for known predictors of infarct size (age, anterior MI, time to revascularization, diabetes, AAR, Rentrop grade, and TIMI flow grade pre-PPCI), using generalized mixed models. No adjustments for multiplicity were performed for secondary endpoints.
Normally distributed continuous variables were expressed as mean AE SD, and comparison was with Student t tests. Non-normally distributed data were expressed as median (25th to 75th quartiles) and analyzed using independent Student t testing where log transformation normalized data, and using Mann-Whitney testing were the degree of skew rendered data nontransformable. Categorical variables were compared using chi-square testing. Clinical outcomes were assessed using time-to-first-event survival analysis (log-rank test with right censoring), and Cox proportional hazard models were fitted to estimate hazard ratios and 95% confidence intervals for treatment comparisons. One hundred patients in each arm gave 81% power to detect a 4% absolute difference in infarct size, assuming a mean of 20% of LV mass and standard deviation of 10% (19, 20) , using a 2-tailed test with alpha ¼ 0.05. New infarct comprising 4% of LV mass is associated with adverse prognosis in patients with revascularization-related injury (21) .
RESULTS

PATIENTS.
In the CMR substudy, 205 consented to participate. Of these, 2 patients were excluded: 1 patient did not complete the early CMR, and in 1 patient, the LGE images were not analyzable. The 
The CvLPRIT CMR Substudy complete revascularization and IRA-only groups in the CMR substudy were well-matched for characteristics, with no statistically significant differences between groups, although there was a trend for more women in the IRA-only group ( Table 1) .
ANGIOGRAPHIC AND PCI DETAILS. Data are shown in Table 2 There was a nonsignificant trend for no-reflow to be more common in the complete revascularization than the IRA group. There was greater usage of a second antianginal agent in patients in the IRA-only group.
PRE-DISCHARGE CMR. Results are displayed in Table 3 . Pre-discharge CMR was undertaken at a median of 3 days post-PPCI in both treatment arms. The prevalence of multiple territory infarcts in the complete revascularization group was double that of the IRA-only group and the number of acute non-IRA infarcts was increased 3-fold in those undergoing complete revascularization (Table 3) . Examples, with corresponding edema images, are shown in Figure 3 , and the location, size of infarct, expected coronary artery territory, and whether the individual patients had an additional non-IRA PCI are shown in Online Table 1 . Eighteen of 20 acute non-IRA infarcts in patents in the complete revascularization group concurred with additional PCI in the relevant non-IRA coronary territory. Five patients randomized to the IRA-only group also had non-IRA acute MI. Two of these patients had treatment crossover and received non-IRA PCI. The first crossover followed ongoing ischemia post-PPCI and was associated with non-IRA MI in the relevant territory. The second crossover resulted from human error, and this patient had a small non-IRA acute MI in the anteroseptum but had non-IRA PCI of the circumflex artery. Six patients in the IRA-only and 5 in the complete revascularization group had chronic infarcts (evidenced by wall thinning). Excluding these patients from the analysis did not affect the results (Online Table 2 ). McCann et al.
MVO was present in more than one-half of all patients, although quantitatively, the amount was very low (median <0.2% of LV mass). In 52 patients (26%), AAR could not be quantified: no artifact, but no edema discernable (n ¼ 33); not performed due to arrhythmia or suboptimal breath-holding (n ¼ 14); or severe artifact (n ¼ 5). AAR and MSI were lower, but not significantly, in the complete revascularization group. LV volume, mass, and ejection fraction were similar in both groups. Reversible perfusion defects were seen in 21% of patients in both groups, and overall ischemic burden was small. When the extent of ischemia was assessed only in patients with reversible perfusion defects, the ischemic burden was not statistically different in the complete revascularization and IRA-only groups. Values are n/N (%), median (interquartile range), mean AE SD, or n (%), unless otherwise noted. The bold type indicates statistically significant p values. *Nonnormally distributed data: analyzed after log transformation with independent Student t testing. †Nonnormally distributed data: analyzed using Mann-Whitney analysis. ‡Because the median and interquartile range was 0 (0 to 0) for both IRA and CR groups, mean AE SD of the results are presented although the data are nonparametrically distributed. §Analyzable edema imaging available in 75 of the complete revascularization group and 77 of the IRA-only group. Table 1 .
DISCUSSION
This is the first detailed study of pre-discharge and follow-up CMR outcomes in a randomized study Late gadolinium-enhanced short-axis images (top row and third rows) and corresponding colocalized edema images (second and fourth rows).
Red asterisks indicate IRA-territory infarct; blue asterisks indicate NIRA-territory infarct(s). Subject ID: (A) (X511); (B) (X612); (C) (X665); (D) (X709); (E) (X757); (F) (X791); (G) (X798); (H) (X808). IRA infarct size and non-IRA PCI are shown in Online Table 1 . NIRA ¼ non-infarct-related artery; other abbreviations as in Figure 2 .
CMR and have been associated with adverse prognosis (21, 25) . In this substudy of CvLPRIT, the prevalence of >1 CMR-detected infarct in patients receiving complete revascularization was double that in the IRA-only arm (23.8% vs. 11.2%), and more than 3-fold for the acute non-IRA infarcts (17.1% vs. 4.8%) (Central Illustration). Previous Q-wave MI was an exclusion criterion in this study, but 4% had a history of previous non-STEMI, and a similar number (6% in the IRA-only and 5% in the complete revasculariza- LGE (21) . Given that the complete revascularization group in the current study had no increase in total infarct size, LV volume, or reduced ejection fraction, it seems unlikely that the short-to medium-term clinical benefits of complete revascularization (22) will be offset in the long term by increased heart failure or sudden cardiac deaths. However, longerterm follow-up of patients in this study is needed to confirm this.
We did not observe any significant differences in myocardial salvage between the treatment groups in this study. Non-IRA revascularization at the time of PPCI could increase perfusion to watershed areas by relieving flow-limiting stenoses, resulting in increased myocardial salvage (26) . Alternatively, resting myocardial perfusion and flow reserve following PCI may actually be reduced, as has been shown in elective patients as a result of distal embolization, particularly when the PCI is associated with new LGE (26, 27) . It may be that both effects are seen with non-IRA PCI resulting in no net benefit with regard to myocardial salvage in the PPCI setting.
Unexpectedly, we also observed no difference in ischemic burden between the groups undergoing follow-up stress perfusion CMR. There are several potential explanations for this finding. First, it is well recognized that even severe angiographic stenoses may not cause ischemia (28, 29) . Second, 11 patients in the IRA-only arm had further PCI before Values are n (%), median (interquartile range), or mean AE SD. A dash indicates that no HR was presentable because 1 or both treatment arms had an incidence of 0.
CI ¼ confidence interval; CVA ¼ cerebrovascular accident; HF ¼ heart failure; HR ¼ hazard ratio; MACE ¼ major adverse cardiovascular events; OR ¼ odds ratio; TIA ¼ transient ischemic attack; other abbreviations as in Table 1 .
The CvLPRIT CMR Substudy the stress CMR that is likely to have reduced ischemic burden in this group. Third, the small number of crossovers from randomization is likely to have diminished the differences in ischemia between the groups. Finally, the stress CMR was undertaken in patients on optimal medical therapy, which may dramatically reduce post-MI ischemia (30) making it more difficult to detect differences between the groups, especially as there was higher use of a second antianginal medication in the IRAonly group. This may also explain why the overall ischemic burden in our study was small (3% to 4%).
It remains to be determined whether ischemia is prognostically important in the PPCI era, especially because medical therapy may result in similar clinical outcomes to a revascularization strategy even in The CvLPRIT CMR Substudy D E C E M B E R 2 2 , 2 0 1 5 : 2 7 1 3 -2 4
patients treated with thrombolysis (30) . Further insight on this subject will be available from the CvLPRIT nuclear substudy.
STUDY LIMITATIONS. The optimal timing to assess infarct size post-STEMI is uncertain (31) . We chose an early time point to enhance participation in the CMR substudy because we felt there could have been a higher dropout rate scanning patients after hospital discharge. MSI was only reliably measured in w75% of patients, and the use of novel T1 or T2
mapping techniques for future studies may lead to a more robust assessment. Current CMR techniques cannot reliably differentiate whether a very small MI, which is not associated with wall thinning, edema, or MVO, is acute or chronic, and this contributed to the slight overreporting of acute non-IRA MIs that were not associated with revascularization in this study.
CONCLUSIONS
An in-hospital complete revascularization strategy in patients with multivessel disease at the time of PPCI is associated with a small increase in type 4a MIs in non-IRA territories, but total infarct size was not significantly different compared with an IRA-only strategy.
